Cagrilintide Shows 11.8% Weight Reduction in REDEFINE 1 Trial Subanalysis
Novo Nordisk’s investigational long-acting amylin analogue cagrilintide achieved an average weight reduction of 11.8% after 68 weeks of treatment, according to data from a new subanalysis of the phase 3 REDEFINE 1 trial presented at the European Association for the Study of Diabetes 2025 congress, held September 15-19, in Vienna.1
Timothy Garvey, MD
Courtesy of University of Alabama at Birmingham
Study participants receiving cagrilintide lost an average of 12.5 kg compared with 2.5 kg in the placebo group, corresponding to 2.3% body weight reduction with placebo. REDEFINE participants had obesity or had overweight with at least 1 weight-related comorbidity and did not have diabetes.1
Around one-third (31.6%) of the study’s 3417 participants receiving cagrilintide achieved weight loss of 15% or more compared with approximately 1 in 20 (4.7%) of those who received placebo. When investigators analyzed the treatment effect without regard to adherence, they reported average reductions of 11.5% with cagrilintide and 3.0% with placebo, with 31.0% and 5.2% of participants, respectively, reaching the 15% or greater threshold, according to the study.1
Favorable Tolerability Profile
“These data highlight the exciting potential of cagrilintide to offer an choice approach for people to lose weight, achieve health-related outcomes and manage their obesity, including a favourable tolerability profile,” lead investigator Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham, said in a statement.2 As with other chronic diseases, he added, it is indeed critically important to have a range of treatment options available in order “to address the individual needs of people with obesity, such as their own specific response to treatment.”2
References
- European Association for the Study of Diabetes. cagrilintide demonstrates significant and sustained weight loss in REDEFINE 1 trial.News release. September 16, 2025.
- University of Alabama at Birmingham. Cagrilintide demonstrates significant and sustained weight loss in REDEFINE 1 trial. News release. September 16, 2025.